Predictors of the rate of BMD loss in older men: findings from the CHAMP study
- 616 Downloads
Though bone loss tends to accelerate with age there are modifiable factors that may influence the rate of bone loss even in very old men.
The aim of this 2-year longitudinal study was to examine potential predictors of change in total hip bone mineral density (BMD) in older men.
The Concord Health and Ageing in Men Project is a population-based study in Sydney, Australia. For this study, 1,122 men aged 70–97 years had baseline and follow-up measures of total hip BMD measured with dual X-ray absorptiometry. Data about mobility, muscle strength, balance, medication use, cognition, medical history and lifestyle factors were collected using questionnaires and clinical assessments. Serum 25-hydroxyvitamin D [25(OH)D] was also measured. Multivariate linear regression models were used to assess relationships between baseline predictors and change in BMD.
Over a mean of 2.2 years, there was a mean annualised loss of total hip BMD of 0.006 g/cm2/year (0.6 %) and hip BMC of 0.14 g/year (0.3 %). Annual BMD loss accelerated with increasing age, from 0.4 % in men aged between 70 and 75 years, to 1.2 % in men aged 85+ years. In multivariate regression models, predictors of faster BMD loss were anti-androgen, thiazolidinedione and loop-diuretic medications, kidney disease, poor dynamic balance, larger hip bone area, older age and lower serum 25(OH)D. Factors associated with attenuated bone loss were walking for exercise and use of beta-blocker medications. Change in BMD was not associated with baseline BMD, smoking, alcohol consumption, BMI, frailty, or osteoarthritis.
There was considerable variation in the rate of hip bone loss in older men. Walking, better balance and beta blockers may attenuate the acceleration of BMD loss that occurs with age.
KeywordsBMC loss Bone mineral density Epidemiology Longitudinal study Men Risk factors
The CHAMP Study is funded by the Australian National Health and Medical Research Council (NHMRC project grant no. 301916) and the Ageing and Alzheimer’s Research Foundation (AARF). Many thanks to the scientists, Lynley Robinson and Beverly White, for assessing the scans and to the participants who have graciously given their time for this study.
The CHAMP study was approved by the Concord Hospital Human Research Ethics Committee. Written and informed consent was given by all participants prior to their inclusion in the study.
Conflicts of interest
- 3.Johnell O, Kanis JA, Oden A, Johansson H, De Laet C, Delmas P, Eisman JA, Fujiwara S, Kroger H, Mellstrom D, Meunier PJ, Melton LJ 3rd, O’Neill T, Pols H, Reeve J, Silman A, Tenenhouse A (2005) Predictive value of BMD for hip and other fractures. J Bone Miner Res 20:1185–1194PubMedCrossRefGoogle Scholar
- 12.Kaptoge S, Reid DM, Scheidt-Nave C, Poor G, Pols HAP, Khaw KT, Felsenberg D, Benevolenskaya LI, Diaz MN, Stepan JJ, Eastell R, Boonen S, Cannata JB, Glueer CC, Crabtree NJ, Kaufman JM, Reeve J (2007) Geographic and other determinants of BMD change in European men and women at the hip and spine. A population-based study from the Network in Europe for Male Osteoporosis (NEMO). Bone 40:662–673PubMedCrossRefGoogle Scholar
- 22.Bleicher K, Cumming RG, Naganathan V, Seibel MJ, Sambrook PN, Blyth FM, Le Couteur D, Handelsman DJ, Creasey H, Waite L (2011) Lifestyle factors, medications and disease influence bone mineral density in older men: findings from the CHAMP study. Osteoporos Int 22:2421–2437PubMedCrossRefGoogle Scholar
- 23.National Health and Medical Research Council (2001) Australian Alcohol Guidelines: Health Risks and Benefits, vol. 2010. Commonwealth of Australia CanberraGoogle Scholar
- 36.Zinman B, Haffner SM, Herman WH, Holman RR, Lachin JM, Kravitz BG, Paul G, Jones NP, Aftring RP, Viberti G (2010) Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes. J Clin Endocrinol Metab 95:134–142Google Scholar
- 37.Schwartz AV, Sellmeyer DE, Vittinghoff E, Palermo L, Lecka-Czernik B, Feingold KR, Strotmeyer ES, Resnick HE, Carbone L, Beamer BA, Park SW, Lane NE, Harris TB, Cummings SR (2006) Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 91:3349–3354PubMedCrossRefGoogle Scholar
- 50.Jamal SA, Swan VJD, Brown JP, Hanley DA, Prior JC, Papaioannou A, Langsetmo L, Josse RG (2010) Kidney function and rate of bone loss at the hip and spine: the Canadian multicentre osteoporosis study. American journal of kidney diseases: the official journal of the National Kidney Foundation 55:291–299CrossRefGoogle Scholar
- 52.Sheu Y, Cauley J, Wheeler V, Patrick A, Bunker C, Ensrud K, Orwoll E, Zmuda J (2010) Age-related decline in bone density among ethnically diverse older men. Osteoporosis International. 1–7Google Scholar
- 63.Cranney A, Horsley T, O’Donnell S, Weiler H, Puil L, Ooi D, Atkinson S, Ward L, Moher D, Hanley D (2007) Effectiveness and safety of vitamin D in relation to bone health. Evid Rep Technol Assess 158:1–235Google Scholar
- 64.Chung M, Balk EM, Brendel M, Ip S, Lau J, Lee J, Lichtenstein A, Patel K, Raman G, Tatsioni A, Terasawa T, Trikalinos TA (2009) Vitamin D and calcium: Systematic review of health outcomes. Evidence Report/Technology Assessment No. 183. (Prepared by Tufts Evidence-based Practice Center under Contract No. 290-2007-10055-I). AHRQ Publication No. 09-E015, Rockville, MD:. Agency for Healthcare Research and QualityGoogle Scholar
- 66.Pasco JA, Henry MJ, Nicholson GC, Brennan SL, Kotowicz MA (2009) Behavioural and physical characteristics associated with vitamin D status in women. Bone 44:1085–1091Google Scholar